NASDAQ:NKTR - Nektar Therapeutics Stock Price, Forecast & News

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.17. The biopharmaceutical company earned $29.22 million during the quarter, compared to analysts' expectations of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.56) earnings per share. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Nektar Therapeutics.

Nektar Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 brokerages have issued 1 year target prices for Nektar Therapeutics' stock. Their forecasts range from $16.00 to $41.00. On average, they anticipate Nektar Therapeutics' share price to reach $30.54 in the next year. This suggests a possible upside of 29.8% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

News articles about NKTR stock have been trending somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Nektar Therapeutics earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Nektar Therapeutics.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Hawkins (HWKN), Incyte (INCY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Netflix (NFLX), Intel (INTC) and AT&T (T).

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.49%), State Street Corp (2.59%), Maverick Capital Ltd. (1.84%), First Trust Advisors LP (1.69%), Geode Capital Management LLC (1.16%) and Goldman Sachs Group Inc. (1.11%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Janus Henderson Group PLC, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., Swiss National Bank, Retirement Systems of Alabama and Bank of America Corp DE. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

NKTR stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., FMR LLC, Goldman Sachs Group Inc., Principal Financial Group Inc., KBC Group NV, Bank of New York Mellon Corp, First Trust Advisors LP and American International Group Inc.. View Insider Buying and Selling for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $23.53.

Nektar Therapeutics has a market capitalization of $4.14 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.

The official website for Nektar Therapeutics is http://www.nektar.com/.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]